8-KLeadership ChangesExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Executive Changes (Mar 8, 2017)

Filed March 8, 2017For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) announced significant changes in its senior scientific leadership through an 8-K filing on March 8, 2017. Dr. Thomas J. Lynch, Jr., a highly respected figure in oncology, will be departing the Board of Directors to assume the role of Executive Vice President and Chief Scientific Officer. This move is intended to bolster the company's scientific and research capabilities, particularly in critical areas like cancer research. Concurrently, the current Chief Scientific Officer, Francis Cuss, will be retiring after a transition period. The appointment of Dr. Lynch comes with a comprehensive compensation package designed to attract and retain top talent, including a substantial base salary, performance-based incentives, and long-term equity awards. Investors should view this as a strategic move by BMY to strengthen its innovation pipeline and leadership in the biopharmaceutical sector, underscoring a commitment to advancing scientific discovery and drug development.

Key Highlights

  • 1Dr. Thomas J. Lynch, Jr. appointed as Executive Vice President and Chief Scientific Officer, effective March 16, 2017.
  • 2Dr. Lynch will resign from the Board of Directors effective March 15, 2017.
  • 3Francis Cuss, EVP and Chief Scientific Officer, will retire from the Company following a three-month transition period.
  • 4Dr. Lynch's compensation package includes a base salary of $1,000,000, significant bonus potential, and substantial long-term incentive awards.
  • 5The Board of Directors' size will temporarily adjust from thirteen to eleven directors.
  • 6Dr. Lynch brings extensive experience from leadership roles at Yale Cancer Center and Massachusetts General Hospital.
  • 7The company has disclosed payments made to Massachusetts General Hospital, where Dr. Lynch held leadership positions, noting they represent a very small percentage of the hospital system's revenue.

Frequently Asked Questions

The primary reason for the announced changes is to strengthen Bristol-Myers Squibb's scientific leadership. The appointment of Dr. Thomas J. Lynch, Jr. as Executive Vice President and Chief Scientific Officer is intended to leverage his expertise in oncology and scientific research to drive innovation and advance the company's drug development pipeline.

Dr. Lynch is a renowned expert in cancer research and has held prominent leadership positions at major medical institutions. His appointment suggests a strategic focus on enhancing the company's oncology portfolio and overall scientific research capabilities, which could positively impact future drug development and market competitiveness.

Dr. Lynch's compensation package is structured to attract and retain top talent. It includes a base salary of $1,000,000, eligibility for annual incentive payouts targeted at 120% of his base salary, and long-term incentive awards valued at $3,375,000, comprising performance share units and market share units. Additionally, he will receive a $1,400,000 cash payment and a $1,400,000 Restricted Stock Unit award.

The filing addresses potential conflicts by disclosing that Bristol-Myers Squibb has made business and charitable payments to Massachusetts General Hospital (MGH), where Dr. Lynch previously held leadership roles. However, it clarifies that these payments in 2016 were approximately $316,000, accounting for less than 0.01% of Partners HealthCare's revenues, suggesting minimal financial entanglement with his prior institution.